First, the knock-down of either Gal-1 or NRP1 showed the same functional impact on restoring drug sensitivity in melanoma cells; moreover, the effects of these treatments were not additive and were instead mutually exclusive, suggesting that the targeted effectors lie in the same signaling pathway. This evidence concerns the gene LGALS1 and melanoma.